The long term goals of this program include the laboratory synthesis of complex natural products possessing desirable biological activity as well as the development of new synthetic methodology that will simplify this task. In addition, we plan to attempt to identify, and to synthesize and test, analogs of these naturally occurring lead compounds which can be accessed synthetically in a more practical manner than the natural compounds themselves. Ongoing investigations on the total synthesis of the complex cytotoxic macrodiolide swinholide will be continued and hopefully brought to completion, as will studies on the promising compound epothilone, which has activity similar to that of taxol. Our studies on the potent and extremely promising anticancer agent bryostatin 1 will continue, and we hope to expand this program aggressively into analog synthesis. Syntheses of leucascandrolide and dolabelide B will be initiated, and analogs of leucascandrolide will be prepared for assay as antifungal and cytotoxic agents. Throughout all of this work, we hope to implement new organic reactions and synthetic strategies which will facilitate the construction of the targeted compounds, as well as prove useful in a broader context.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM028961-21
Application #
6470158
Study Section
Medicinal Chemistry Study Section (MCHA)
Program Officer
Schwab, John M
Project Start
1981-06-01
Project End
2006-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
21
Fiscal Year
2002
Total Cost
$401,792
Indirect Cost
Name
University of Utah
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Petersen, Mark E; Kedei, Noemi; Lewin, Nancy E et al. (2016) Replacement of the Bryostatin A- and B-Pyran Rings With Phenyl Rings Leads to Loss of High Affinity Binding With PKC. Tetrahedron Lett 57:4749-4753
Kelsey, Jessica S; Cataisson, Christophe; Chen, Jinqiu et al. (2016) Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin. Mol Carcinog 55:2183-2195
Kedei, Noemi; Kraft, Matthew B; Keck, Gary E et al. (2015) Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships. J Nat Prod 78:896-900
Kraft, Matthew B; Poudel, Yam B; Kedei, Noemi et al. (2014) Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core. J Am Chem Soc 136:13202-8
Kedei, Noemi; Chen, Jin-Qiu; Herrmann, Michelle A et al. (2014) Molecular systems pharmacology: isoelectric focusing signature of protein kinase C? provides an integrated measure of its modulation in response to ligands. J Med Chem 57:5356-69
Kedei, N; Telek, A; Michalowski, A M et al. (2013) Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action. Biochem Pharmacol 85:313-24
Keck, Gary E; Poudel, Yam B; Rudra, Arnab et al. (2012) Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity. Bioorg Med Chem Lett 22:4084-8
Keck, Gary E; Poudel, Yam B; Cummins, Thomas J et al. (2011) Total synthesis of bryostatin 1. J Am Chem Soc 133:744-7
Kedei, Noemi; Telek, Andrea; Czap, Alexandra et al. (2011) The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line. Biochem Pharmacol 81:1296-308
Keck, Gary E; Poudel, Yam B; Rudra, Arnab et al. (2010) Molecular modeling, total synthesis, and biological evaluations of C9-deoxy bryostatin 1. Angew Chem Int Ed Engl 49:4580-4

Showing the most recent 10 out of 32 publications